Literature DB >> 29167218

Concomitant AIDS cholangiopathy and Fanconi syndrome as complications of HIV in a single patient.

Robert Maweni1, Jins Kallampallil1, Szewai Leong2, Srikanth Akunuri1.   

Abstract

We describe the case of a 50-year-old woman presenting to our acute medicine department with generalised non-specific symptoms on a background of HIV managed on triple therapy (tenofovir, lamivudine and zidovudine). On admission, she was noted to be acidotic with proteinuria, glycosuria, hypophosphataemia and generalised body pain, and was diagnosed with Fanconi's renotubular syndrome secondary to tenofovir. It was also noted that she had elevated liver dysfunction markers, and an MRI of the liver revealed a focal stricture near the ampulla of Vater, resulting in a diagnosis of AIDS cholangiopathy. These two diagnoses are rare complications of HIV, and the presence of both these pathologies in a single patient has never been reported in the literature before, and we therefore believe that this case is the first of its kind. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  hiv / aids; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2017        PMID: 29167218      PMCID: PMC5720260          DOI: 10.1136/bcr-2017-222333

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

1.  Fanconi syndrome and renal failure induced by tenofovir: a first case report.

Authors:  David Verhelst; Matthieu Monge; Jean-Luc Meynard; Bruno Fouqueray; Béatrice Mougenot; Pierre-Marie Girard; Pierre Ronco; Jerome Rossert
Journal:  Am J Kidney Dis       Date:  2002-12       Impact factor: 8.860

2.  HIV/AIDS cholangiopathy: clinical spectrum, cholangiographic features and outcome in 30 patients.

Authors:  Harshad Devarbhavi; Teena Sebastian; Sandeep M Seetharamu; Dheeraj Karanth
Journal:  J Gastroenterol Hepatol       Date:  2010-10       Impact factor: 4.029

Review 3.  Tenofovir Alafenamide.

Authors:  Amanda K Gibson; Bhavik M Shah; Puja H Nambiar; Jason J Schafer
Journal:  Ann Pharmacother       Date:  2016-07-28       Impact factor: 3.154

4.  Prognostic factors for the survival of patients with AIDS cholangiopathy.

Authors:  Wei-Fang Ko; John P Cello; Stanley J Rogers; Anthony Lecours
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

5.  Long-term follow-up of endoscopic retrograde cholangiopancreatography sphincterotomy for patients with acquired immune deficiency syndrome papillary stenosis.

Authors:  J P Cello; M F Chan
Journal:  Am J Med       Date:  1995-12       Impact factor: 4.965

6.  Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.

Authors:  Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt
Journal:  J Infect Dis       Date:  2016-03-29       Impact factor: 5.226

7.  Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism.

Authors:  X M Chen; S A Levine; P Tietz; E Krueger; M A McNiven; D M Jefferson; M Mahle; N F LaRusso
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

8.  AIDS Cholangiopathy in an Asymptomatic, Previously Undiagnosed Late-Stage HIV-Positive Patient from Kenya.

Authors:  Yiming Gao; Kathryn Chin; Yehia Y Mishriki
Journal:  Int J Hepatol       Date:  2011-04-04

9.  Pre-exposure prophylaxis of HIV.

Authors:  Smriti Naswa; Y S Marfatia
Journal:  Indian J Sex Transm Dis AIDS       Date:  2011-01

10.  Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.

Authors:  Nicholas T Funderburg; Grace A McComsey; Manjusha Kulkarni; Tammy Bannerman; Jessica Mantini; Bernadette Thornton; Hui C Liu; Yafeng Zhang; Qinghua Song; Liang Fang; Jason Dinoso; Andrew Cheng; Scott McCallister; Marshall W Fordyce; Moupali Das
Journal:  EBioMedicine       Date:  2016-10-11       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.